Company Overview
About Karius
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens (bacteria, fungi, viruses, parasites) in seriously ill patients. The test is used when conventional cultures and targeted diagnostics fail, providing clinicians at transplant centers, children''s hospitals, and ICUs with a comprehensive pathogen report within 24 hours.
Business Model & Competitive Advantage
Karius has raised $409M in total funding. In May 2024, the company closed a $100M Series C co-led by Khosla Ventures, 5AM Ventures, and Gilde Healthcare, with participation from SoftBank Vision Fund 2, General Catalyst, HBM Healthcare Investments, and others. The Karius Test is currently used across 400+ healthcare institutions — including 90+ transplant centers and 40+ children''s hospitals in the U.S. In April 2025, Karius launched Karius Focus | BAL, a microbial cell-free DNA test specifically designed to identify pathogens causing pneumonia and other lung infections from bronchoalveolar lavage samples, available nationwide.
Competitive Landscape 2025–2026
Karius operates at the intersection of infectious disease medicine and the antimicrobial resistance (AMR) crisis — its broad-spectrum pathogen detection can help clinicians de-escalate empiric broad-spectrum antibiotic use when specific pathogens are identified, contributing to AMR stewardship. The company competes with traditional culture-based diagnostics and targeted molecular tests, but its non-invasive, comprehensive approach is increasingly viewed as a standard of care for immunocompromised and critically ill patients.
Key Differentiators
Market Leader
Karius is recognized as a market leader in the Life Sciences & BioTech sector, demonstrating strong industry presence and customer trust.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Saama Analytics
Saama Analytics is the leading AI-driven clinical analytics and data management platform for the life sciences industry, positioning itself as the "#1 in AI Clinical Analytics" based on customer adopt
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Compare Karius with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Karius? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Karius Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Karius vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →